Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

This is a first-in-human study testing ISM6331 — a new drug targeting the Hippo signaling pathway (a molecular pathway that controls cell growth) — in patients with advanced malignant mesothelioma (a rare cancer often linked to asbestos exposure) or other advanced solid tumors with specific genetic alterations in this pathway. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic malignant mesothelioma, or another solid tumor with documented Hippo pathway dysregulation - For mesothelioma: you have had prior treatment including immunotherapy and platinum-based chemotherapy - You have measurable disease on imaging - You are in good general health (ECOG ≤1) - Your blood, liver, and kidney function are adequate **You may NOT be eligible if...** - You have had certain prior therapies that conflict with study requirements - You are pregnant or breastfeeding - You have active serious infections or significant autoimmune disease - Your general health status is poor (ECOG above 1) - You have had recent major cardiac events Talk to your doctor to see if this trial is right for you.